Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Becton Dickinson and Co, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Becton Dickinson and Co, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Becton Dickinson and Co, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Becton Dickinson and Co, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Becton Dickinson and Co, Medical Devices Deals, 2011 to YTD 2017 11
Becton Dickinson and Co, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Becton Dickinson and Co, Pharmaceuticals & Healthcare, Deal Details 16
Venture Financing 16
GenCell Biosystems Raises US$3.5 Million In Seed Financing Round 16
Sirigen Secures US$3 Million In Venture Financing 17
Private Equity 18
CareFusion Reportedly Elicits Acquisition Interest From Private Equity Firms 18
Partnerships 19
Selah Genomics, Greenville Health, DecisionQ and Becton Dickinson Enter into Agreement 19
GenCell Biosystems To Enter Into Agreement With Fiocruz, Institute Of Molecular Biology Of Parana And Immunobiological Technology Institute To Develop Clinical Screening Systems 20
Sartorius Stedim Biotech Enters Into Co-Development Agreement With BD Diagnostic 21
NanoString Technologies And BD Biosciences Enter Into Agreement To Develop Single Cell Isolation And Analysis Workflow 22
TCGRx Enters Into Co-Marketing Agreement With CareFusion For Medication Delivery Solutions 23
CareFusion Enters Into Distribution Agreement With ResMed 24
SANYO North America Enters Into Co-Promotion Agreement With BD Biosciences 25
Licensing Agreements 26
Advanced Inhalation Therapies Enters into Licensing Agreement with CareFusion 26
Equity Offering 27
Becton Dickinson Raises USD2.47 Billion in Public Offering of Shares 27
Becton Dickinson Raises USD2.47 Billion in Public Offering of Depositary Shares 29
Becton, Dickinson Files Registration Statement For Public Offering Of Securities 31
Debt Offering 32
Becton, Dickinson to Raise USD500 Million in Public Offering of Floating Rate Notes Due 2022 32
Becton, Dickinson to Raise USD1.5 Billion in Public Offering of 4.669% Notes Due 2047 33
Becton, Dickinson to Raise USD788 Million in Public Offering of 0.368% Notes Due 2019 34
Becton, Dickinson to Raise USD1.8 Billion in Public Offering of 2.894% Notes Due 2022 35
Becton, Dickinson to Raise USD1 Billion in Public Offering of 2.404% Notes Due 2020 36
Becton, Dickinson to Raise USD1.75 Billion in Public Offering of 3.363% Notes Due 2024 37
Becton, Dickinson to Raise USD2.4 Billion in Public Offering of 3.7% Notes Due 2027 38
Becton, Dickinson to Raise USD725 Million in Public Offering of 2.133% Notes Due 2019 39
Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million 40
Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million 42
Becton, Dickinson Raises USD1.25 Billion in Public Offering of 1.8% Notes Due 2017 44
Becton, Dickinson Raises USD1.25 Billion in Public Offering of 2.675% Notes Due 2019 46
Becton, Dickinson Raises USD1.75 Billion in Public Offering of 3.734% Notes Due 2024 48
Becton, Dickinson Raises USD1.2 Billion in Public Offering of 4.685% Notes Due 2044 50
Becton, Dickinson Raises USD750 Million in Public Offering of Floating Rate Notes Due 2016 52
CareFusion Raises USD300 Million in Private Placement of Notes Due 2017 54
CareFusion Raises USD400 Million in Public Offering of Notes Due 2024 56
CareFusion Raises USD300 Million in Public Offering of Notes Due 2044 57
CareFusion Completes Private Placement Of Notes Due 2023 For US$300 Million 58
Becton, Dickinson Completes Public Offering Of Notes Due 2016 For US$500 Million 59
Becton, Dickinson Completes Public Offering Of Notes Due 2021 For US$1 Billion 60
Asset Transactions 61
Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 61
Acquisition 62
BD Acquires CRISI Medical Systems 62
Becton, Dickinson Acquires GenCell Biosystems 63
Becton, Dickinson Acquires Sirigen, Developer Of Polymer Dyes 64
Becton, Dickinson Acquires KIESTRA, Provider Of Lab Automation Solutions 66
Becton Dickinson and Co – Key Competitors 67
Becton Dickinson and Co – Key Employees 68
Becton Dickinson and Co – Locations And Subsidiaries 70
Head Office 70
Other Locations & Subsidiaries 70
Recent Developments 77
Strategy And Business Planning 77
Jan 26, 2017: New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes Through Collaboration 77
Financial Announcements 78
Aug 03, 2017: BD Announces Results For 2017 Third Fiscal Quarter 78
May 02, 2017: BD Announces Results For 2017 Second Fiscal Quarter 80
Feb 02, 2017: BD Announces Results For 2017 First Fiscal Quarter 82
Nov 03, 2016: BD Announces Results For 2016 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2017 Guidance 84
Aug 04, 2016: BD Announces Results For 2016 Third Fiscal Quarter 86
May 05, 2016: BD Announces Results For 2016 Second Fiscal Quarter 88
Feb 03, 2016: BD Announces Results For 2016 First Fiscal Quarter 90
Corporate Communications 92
Apr 23, 2017: BD Announces Appointment Of Tom Polen As President 92
Jul 28, 2016: BD Names R. Andrew Eckert To Board Of Directors 93
Legal and Regulatory 94
Aug 18, 2017: District Court Issues Final Judgment – Retractable Technologies v. Becton, Dickinson 94
Mar 21, 2017: Retractable Technologies Announces Litigation Updates 95
Government and Public Interest 96
Jun 06, 2017: BD Releases 2016 Sustainability Report 96
Mar 28, 2017: BD Announces Success of Helping Build Healthy Communities Program, Launches New Effort Focused on Medication Therapy Management 97
Product News 98
Sep 12, 2017: BD Expands Genomics Portfolio with New Single Cell Platform for RNA Expression Analysis 98
Feb 08, 2016: BD Launches BD FACSymphony High-Speed Cell Analyzer to Enable Identification and Analysis of Rare Cell Types 99
Jan 17, 2017: BD Launches Reagents to Simplify Single Cell Research 100
Other Significant Developments 101
Apr 03, 2017: BD Launches “Power in Prevention” Program to Help Minimize Risk of Infections during Surgical Process at 2017 AORN Annual Conference 101
Feb 16, 2017: BD Initiates New Industry Alliance To Combat Rising Opioid Crisis 102
Appendix 103
Methodology 103
About GlobalData 103
Contact Us 103
Disclaimer 103
Becton Dickinson and Co, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Becton Dickinson and Co, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Becton Dickinson and Co, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Becton Dickinson and Co, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Becton Dickinson and Co, Deals By Therapy Area, 2011 to YTD 2017 10
Becton Dickinson and Co, Medical Devices Deals, 2011 to YTD 2017 11
Becton Dickinson and Co, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
GenCell Biosystems Raises US$3.5 Million In Seed Financing Round 16
Sirigen Secures US$3 Million In Venture Financing 17
CareFusion Reportedly Elicits Acquisition Interest From Private Equity Firms 18
Selah Genomics, Greenville Health, DecisionQ and Becton Dickinson Enter into Agreement 19
GenCell Biosystems To Enter Into Agreement With Fiocruz, Institute Of Molecular Biology Of Parana And Immunobiological Technology Institute To Develop Clinical Screening Systems 20
Sartorius Stedim Biotech Enters Into Co-Development Agreement With BD Diagnostic 21
NanoString Technologies And BD Biosciences Enter Into Agreement To Develop Single Cell Isolation And Analysis Workflow 22
TCGRx Enters Into Co-Marketing Agreement With CareFusion For Medication Delivery Solutions 23
CareFusion Enters Into Distribution Agreement With ResMed 24
SANYO North America Enters Into Co-Promotion Agreement With BD Biosciences 25
Advanced Inhalation Therapies Enters into Licensing Agreement with CareFusion 26
Becton Dickinson Raises USD2.47 Billion in Public Offering of Shares 27
Becton Dickinson Raises USD2.47 Billion in Public Offering of Depositary Shares 29
Becton, Dickinson Files Registration Statement For Public Offering Of Securities 31
Becton, Dickinson to Raise USD500 Million in Public Offering of Floating Rate Notes Due 2022 32
Becton, Dickinson to Raise USD1.5 Billion in Public Offering of 4.669% Notes Due 2047 33
Becton, Dickinson to Raise USD788 Million in Public Offering of 0.368% Notes Due 2019 34
Becton, Dickinson to Raise USD1.8 Billion in Public Offering of 2.894% Notes Due 2022 35
Becton, Dickinson to Raise USD1 Billion in Public Offering of 2.404% Notes Due 2020 36
Becton, Dickinson to Raise USD1.75 Billion in Public Offering of 3.363% Notes Due 2024 37
Becton, Dickinson to Raise USD2.4 Billion in Public Offering of 3.7% Notes Due 2027 38
Becton, Dickinson to Raise USD725 Million in Public Offering of 2.133% Notes Due 2019 39
Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million 40
Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million 42
Becton, Dickinson Raises USD1.25 Billion in Public Offering of 1.8% Notes Due 2017 44
Becton, Dickinson Raises USD1.25 Billion in Public Offering of 2.675% Notes Due 2019 46
Becton, Dickinson Raises USD1.75 Billion in Public Offering of 3.734% Notes Due 2024 48
Becton, Dickinson Raises USD1.2 Billion in Public Offering of 4.685% Notes Due 2044 50
Becton, Dickinson Raises USD750 Million in Public Offering of Floating Rate Notes Due 2016 52
CareFusion Raises USD300 Million in Private Placement of Notes Due 2017 54
CareFusion Raises USD400 Million in Public Offering of Notes Due 2024 56
CareFusion Raises USD300 Million in Public Offering of Notes Due 2044 57
CareFusion Completes Private Placement Of Notes Due 2023 For US$300 Million 58
Becton, Dickinson Completes Public Offering Of Notes Due 2016 For US$500 Million 59
Becton, Dickinson Completes Public Offering Of Notes Due 2021 For US$1 Billion 60
Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 61
BD Acquires CRISI Medical Systems 62
Becton, Dickinson Acquires GenCell Biosystems 63
Becton, Dickinson Acquires Sirigen, Developer Of Polymer Dyes 64
Becton, Dickinson Acquires KIESTRA, Provider Of Lab Automation Solutions 66
Becton Dickinson and Co, Key Competitors 67
Becton Dickinson and Co, Key Employees 68
Becton Dickinson and Co, Other Locations 70
Becton Dickinson and Co, Subsidiaries 71